Arcturus Therapeutics
ARCT
128 hedge funds and large institutions have $354M invested in Arcturus Therapeutics in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 49 increasing their positions, 33 reducing their positions, and 14 closing their positions.
102% more call options, than puts
Call options by funds: $11.1M | Put options by funds: $5.49M
48% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 33
2.52% more ownership
Funds ownership: 81.33% → 83.85% (+2.5%)
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 130 → 128 (-2)
39% less capital invested
Capital invested by funds: $578M → $354M (-$225M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.58M |
| 2 |
BlackRock
New York
|
+$4.09M |
| 3 |
Millennium Management
New York
|
+$4.01M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$3.76M |
| 5 |
Goldman Sachs
New York
|
+$1.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$8.07M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.94M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.25M |
| 4 |
Rafferty Asset Management
New York
|
-$2M |
| 5 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$1.81M |
ARCT Hedge Fund Activity: Q2 2022 in Review
128 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q2 2022, worth a combined $354M — down 39% from $578M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ARCT positions and 14 closed out — a net gain of 1 holder — while 49 added to existing stakes and 33 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $9.58M. The largest seller was State Street, cutting an estimated $8.07M.
- 128 institutional investors held Arcturus Therapeutics (ARCT) as of Q2 2022, down from 130 in Q1 2022.
- Funds reported $354M of Arcturus Therapeutics stock for Q2 2022, down 39% quarter-over-quarter.
- 15 funds opened new Arcturus Therapeutics positions in Q2 2022 and 14 closed out, a net change of +1 holder.
- The largest Arcturus Therapeutics buyer in Q2 2022 was Point72 Asset Management, an estimated $9.58M added.
- The largest Arcturus Therapeutics seller in Q2 2022 was State Street, an estimated $8.07M sold.
Based on aggregated 13F filings for Q2 2022.